NCT06945978 Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
| NCT ID | NCT06945978 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Benedito Mauro Rossi |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-21 |
| Primary Completion | 2027-10 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with metastatic PDAC; * Patients who will start treatment with FOLFIRINOX; * 18 years or older; * Who agree to participate in the study by signing the Informed Consent Form; Exclusion Criteria: * Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment; * Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.